Piflufolastat F not checked
Lantheus Medical Imaging · 18F-DCFPyL
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants will receive a single dose of 333 MBq (9 mCi) \[296 MBq-370 MBq (8 mCi - 10 mCi)\] PYLARIFY injection followed by a single whole-body PET/CT or PET/MRI scan acquired at 1 to 2 hours post-dosing”In the company’s words, NCT06074510 on ClinicalTrials.gov
- Tested for
- Prostate Cancer, Clear Cell Renal Cell Carcinoma
- Main trialPhase 4
- “The purpose of this study is to learn whether PYLARIFY PET imaging (study scan) can safely and accurately detect the presence or absence of prostate cancer growing beyond the prostate gland in men with favorable intermediate risk prostate cancer. Participants will receive a single dose of PYLARIFY injection followed by a single whole-body PET/CT or PET/MRI scan acquired at 1 to 2 hours after PYLARIFY injection. Participants with positive study scan results that are suspicious for prostate cancer outside of the prostate gland may be asked to undergo additional diagnostic test(s) and/or…”In the company’s words, NCT06074510 on ClinicalTrials.gov
- Other names
- PYLARIFY · 18F-DCFPyL
Other drugs for Prostate Cancer
- ApalutamideJohnson & Johnson (Janssen) · Phase 3
- 64Cu-SAR-bisPSMAClarity Pharmaceuticals Ltd · Phase 3
- Abiraterone acetateJohnson & Johnson (Janssen) · Phase 3
- 68Ga-PSMA-11Telix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- EnzalutamidePfizer · Astellas · Phase 3
- MevrometostatPfizer · Phase 3
Coming up0
No dates coming up.
Changes2
Last 90 days- 17 NovStatus changed: Active, not recruiting to Completed · ClinicalTrials.gov NCT06074510
- 17 NovCompletion date moved: 2026-09 to 2026-08-28 · ClinicalTrials.gov NCT06074510
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Completed | 28 Aug 2026 | PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer | |
| Phase 2/3Withdrawn | Sep 2027 | Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026